Table 1.
Patient characteristics.
| Patients (n) | 27 | |
| Age | 56 ± 12.9 | |
| Sex | ||
| Male | 9/27 (33.3%) | |
| Female | 18/27 (66.7%) | |
| WHO Grade | ||
| 2 | 1/27 (3.8%) | |
| 3 | 4/27 (15.4%) | |
| 4 | 22/27 (81.5%) | |
| Lesion laterality (exclusive) | ||
| Left only | 9/27 (33.3%) | |
| Right only | 8/27 (29.6%) | |
| Bilateral | 10/27 (37.0%) | |
| Neuroanatomical Tumor Spread (non-exclusive counts *) | ||
| Left hemisphere | Σ19 | |
| Left frontal | 3 | |
| Left temporal | 9 | |
| Left parietal | 3 | |
| Left occipital | 0 | |
| Left cerebellum | 0 | |
| Left central | 4 | |
| Left thalamus | 0 | |
| Right hemisphere | Σ18 | |
| Right frontal | 6 | |
| Right temporal | 5 | |
| Right parietal | 2 | |
| Right occipital | 2 | |
| Right cerebellum | 0 | |
| Right central | 1 | |
| Right thalamus | 2 | |
| Corpus callosum | 1 | |
| EGFR amplified | ||
| No | 19 (70.4%) | |
| Yes | 8 (29.6%) | |
| IDH status | EGFR amplified | EGFR not amplified |
| Mutated | 1/27 (3.7%) | 8/27 (29.6%) |
| Wildtype | 7/27 (25.9%) | 11/27 (40.7%) |
| MGMT methylation status | EGFR amplified | EGFR not amplified |
| Unmethylated | 7/27 (25.9%) | 13/27 (48.1%) |
| Methylated | 1/27 (3.7%) | 6/27 (22.2%) |
* Non-exclusive counts: a tumor may involve multiple regions and/or both hemispheres; totals can exceed n = 27. Exclusive lesion laterality (Left-only/Right-only/Bilateral) is reported above.